NCT04218617
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patient must have spinal metastasis from C3 to L5 based on bone scan, CT, PET, or MRI
Exclusions: Patients with spinal cord compression; Patients who previously underwent spine stereotactic radiosurgery to the vertebrae of interest
https://ClinicalTrials.gov/show/NCT04218617